In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Brought to you by

PhotoCure grants exclusive Hexvix rights to GE Healthcare; deal ends

Jan 2006

Executive Summary

PhotoCure ASA (drugs and devices for cancer) has licensed GE Healthcare exclusive worldwide rights (outside of the US and Nordic countries) to market and distribute the imaging agent Hexvix (hexaminolevulinate) for the diagnosis and monitoring of bladder cancer. GE also gets an option for marketing and distribution in the US.
Deal Industry
  • Biotechnology
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By